(Last Updated On: October 26, 2018)
Authors: Eunice Kaye M. Rayos-Lopez, MD, Mary Catherine T. Galang, MD, DPDS,  Dr. Ricky H. Hipolito, MD, DPDS, Ma. Teresita G. Gabriel, MD, FPDS

Abstract

Introduction: Scleromyxedema is a rare skin disorder characterized by fibroblast proliferation and mucin deposition in the dermis, in the absence of thyroid disease. The precise mechanisms whereby increased fibroblast activity results in mucin deposition remain to be defined, but the etiology of the disorder still remains to be unknown.

Case Summary: We report a rare case of a 47-year-old female with a three-year history of multiple erythematous to light brown, firm, waxy, slightly pruritic papules and plaques on the earlobes, nose, buttocks and extremities. Dermatologic examination showed multiple 2-3mm firm, waxy, closely-spaced papules and plaques symmetrically distributed on the earlobes, nose, arms, buttocks, extending into thighs and knees. Routine laboratory tests and thyroid function test results were within the normal range. Skin punch biopsy was done on the right arm and histopathologic results were consistent with diagnosis of papular mucinosis. Patient was treated with topical steroids and colchicine with significant improvement of the lesions.

Conclusion: Scleromyxedema is a rare, chronic and unpredictable disease with no specific definitive treatment. Most commonly used therapies are intravenous and immunogloblulin (IVIg) and systemic steroids. Few data are available on more cost-effective treatment options. Colchicine should be further explored as cost-effective and safer alternative treatment in the management of this disease.

Citation

Lopez, E., Galang, MC., Hipolito, R.& Gabriel, MT. (2017). Scleromyxedema in a 47-year-old female treated with colchicine and topical steroids. Journal of the Philippine Dermatological Society, 26(2), 67-70.

 

Keywords

Scleromyxedema, Papular mucinosis, Lichen myxedematosus, Colchicine

  1. Rongioletti, F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273-81.
  2. Rongioletti, F, Rebora, A. The new cutaneous mucinoses: A review with an up-to-date classification of cutaneous mucinoses. J Am Acad Dermatol 1991; 24:265-70.
  3. Rongioletti F, Merlo G, Cinotti E, et. al. Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69:66-72.
  4. Bolognia, J, Jorizzo, J, Schaffer, J. Dermatology. 3rd edition, 2012.
  5. Vanderschueren, S, Mylle, M, Dierickx, D, et.al. Monoclonal Gammopathy of Undetermined Significance: Significant beyond hematology. Mayo Clinic Proceedings 2009; 84:842-845.
  6. Samuelsson A, Towers, TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-6.
  7. Desai AD, James WD. Lichen myxedematosus. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson IC, editors. Treatment of skin disease: comprehensive therapeutic strategies. 2nd London (UK): Elsevier, 2006. pp.343-4.
  8. Cunningham, B, Kirchmann, T, Woodley, D. Colchicine for Epidermolysis Bullosa Acquisita. J Am Acad Dermatol 1996; 34:781-4.

More Articles